Integrum develops the OPRATM Implant System, a revolutionary implant technology based on the company’s deep expertise and innovations in osseointegration, that help amputees regain normal mobility and quality of life.
The current patent includes claims covering the system as a whole, including the anchoring solution for attaching a prosthesis into the human body as well as the abutment and the abutment screw. These claims extend beyond transfemoral applications, which currently make up the majority of treatment cases, to include treatment in other types of long bone prosthetic applications, such as the upper arm or lower leg.
Further, the claims cover design features for the connection between the abutment and the fixture, allowing a pathway for communication of physical and biophysical signals between inside and outside of the human body. Such design aspects are of vital importance to, for example, the e-OPRATM Implant System – Integrum’s state-of-the-art mind-controlled robotic prosthesis.
The patent grants Integrum exclusivity to OPRATM Implant System ranging from October 11th ,2022, until 2044 and is of vital importance to the continued commercial success on the world’s largest medical technology market.
“We are encouraged by this further recognition of Integrum as an innovative leader developing state-of-the-art products within osseointegration. We are currently working ambitiously to implement OPRATM Implant System as the new standard of care in amputation treatment, and the new patent offers broad protection for a long time ahead”, comments Rickard Brånemark, CEO of Integrum.
For more information please contact:
Rickard Brånemark, CEO. +46 (0) 70 846 10 61, E-mail: email@example.com
Dennis Baecklund, CFO. +46 (0) 72 556 68 69, E-mail: firstname.lastname@example.org
Erik Penser Bank is Certified Adviser and can be reached at +46 (0) 8-463 8000.